Veracyte, Inc. is a healthcare company specializing in genomic diagnostics. It develops and commercializes tests that aid in the diagnosis and management of various cancers and other diseases. The company's core products include genomic tests for thyroid, lung, and other cancers, primarily targeting the oncology market. Major business segments consist of diagnostic testing services and research collaborations. The primary revenue source is derived from the sale of these diagnostic tests to healthcare providers and institutions.
The investment profile of Veracyte is more aligned with growth investors, given its focus on innovative diagnostic solutions and potential market expansion. The company does not currently offer dividends, making it less suitable for income-focused investors. The stock may appeal to those looking for long-term capital appreciation, though it carries higher risk due to market volatility and competitive pressures.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-12 | Hold | Sell | Weak momentum and high risk; cautious outlook advised. |
| 2026-09-06 | Sell | Hold | Weak momentum and high risk; cautious approach advised. |
| 2026-08-29 | Buy | Sell | Mixed performance; high risk with uncertain momentum. |
| 2026-08-27 | Sell | Buy | Strong EPS growth and positive market momentum. |
| 2026-08-22 | Hold | Sell | Positive EPS surprise, but negative momentum concerns persist. |
| 2026-08-15 | Buy | Hold | Weak momentum and high risk overshadow potential growth. |
| 2026-08-07 | Sell | Buy | Positive EPS surprise, but recent momentum is weak. |
| 2026-08-01 | — | Sell | High volatility and negative momentum raise significant concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-09 | UBS | Update | — → 65 | 42.45 |
| 2026-08-04 | Morgan Stanley | Target Lowered | 47 → 44 | 44.4925 |
| 2026-08-04 | Stephens | Target Lowered | 68 → 55 | 44.85 |
| 2026-08-04 | Piper Sandler | Target Lowered | 66 → 54 | 44.85 |
| 2026-08-03 | Canaccord Genuity | Target Lowered | 60 → 50 | 46.32 |
| 2026-07-31 | Needham | Target Raised | — → 69 | 59.78 |
| 2026-07-15 | Piper Sandler | Update | — → 66 | 56.62 |
| 2026-07-14 | Canaccord Genuity | Target Raised | 42 → 60 | 57.48 |
| 2026-07-09 | Morgan Stanley | Target Raised | 37 → 47 | 56.12 |
| 2026-06-29 | Guggenheim | Target Raised | 45 → 65 | 60.49 |
| 2026-06-01 | Needham | Target Raised | — → 57 | 48.3819 |
| 2026-05-06 | UBS | Target Raised | 48 → 52 | 39.4439 |
| 2026-05-06 | Canaccord Genuity | Target Raised | 40 → 42 | 32.97 |
| 2026-03-05 | Morgan Stanley | Target Lowered | — → 37 | 34.68 |
| 2026-01-05 | Guggenheim | Target Raised | 45 → 50 | 42.945 |
